TLDR The study found that certain microRNAs are higher in the cells and lower in the fluid of women with a specific type of polycystic ovary syndrome, and one microRNA could potentially help diagnose the condition.
The study examined the expression of miR-93 and miR-21 in granulosa cells (GCs) and follicular fluid (FF) of patients with polycystic ovary syndrome (PCOS), specifically comparing hyperandrogenic (HA) and normo-androgenic (NA) PCOS patients to healthy controls. It was found that both miR-93 and miR-21 were significantly higher in the GCs of HA PCOS patients than in NA patients, while their levels in FF were significantly lower in the HA group compared to controls. Additionally, the study observed a downregulation of SMAD7 and TGFBR2 mRNA, components of the TGFB signaling pathway, in the GCs of HA PCOS patients, with a corresponding decrease in TGFBR2 protein levels. The expression of these microRNAs in GCs was positively correlated with free testosterone and free androgen index in the PCOS group. The study also demonstrated that dihydrotestosterone (DHT) treatment could induce the upregulation of these microRNAs, an effect that was blocked by the androgen receptor blocker bicalutamide. miR-21 was identified as a potential biomarker for PCOS with a sensitivity of 94.8% and specificity of 39.1%, and while combining microRNAs did not improve the overall diagnostic accuracy, it did increase specificity to 47.8% and slightly reduced sensitivity to 87.1%. The number of participants in each group was not specified in the summary.
50 citations,
January 2016 in “The Journal of Clinical Endocrinology and Metabolism” Certain microRNAs in the fluid around eggs are linked to Polycystic Ovary Syndrome and may help diagnose it.
991 citations,
January 2011 in “Nature Reviews Endocrinology” The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.
118 citations,
February 2009 in “Fertility and Sterility” Most women with PCOS have high levels of male hormones, and free testosterone is the best marker for this.
4809 citations,
January 2004 in “Fertility and Sterility” The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.
1947 citations,
September 1995 in “New England journal of medicine/The New England journal of medicine” PCOS is a common hormonal disorder causing irregular periods and increased hair growth, linked to insulin resistance and long-term health issues.
1 citations,
January 2024 in “International journal of molecular sciences” MicroRNAs could be key biomarkers and therapeutic targets for PCOS.
3 citations,
January 2023 in “International Journal of Molecular Sciences” Heat Shock Proteins are important in the development of Polycystic Ovarian Syndrome and could be targets for new treatments.
October 2023 in “Frontiers in endocrinology” Effective PCOS treatments require targeting specific signaling pathways.
883 citations,
August 2016 in “Nature Reviews Disease Primers” Polycystic Ovary Syndrome (PCOS) is a common condition in women that can cause metabolic, reproductive, and psychological issues, and requires lifestyle changes and medication for management.
1 citations,
January 2023 in “Metabolites” Changes in gut bacteria can contribute to the development of Polycystic Ovary Syndrome (PCOS), affecting metabolism, immunity, and causing inflammation. Treatments may involve adjusting these factors.
